Mesoblast Limited (ASX: MSB; Nasdaq: MESO) has highlighted the successful commercial launch of its flagship therapy, Ryoncil® (remestemcel-L-rknd), at two major global healthcare conferences — Morgan Stanley and Cantor Fitzgerald’s Annual Global Healthcare events in New York. This milestone underscores Mesoblast’s position as a global leader in allogeneic cellular medicines for inflammatory diseases.

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) has presented important data from its ATH434-201 Phase 2 clinical trial at the 150th Annual Meeting of the American Neurological Association (ANA) in Baltimore, USA. The trial focused on Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease. These results mark a significant milestone for Alterity as it moves closer to providing the first disease-modifying therapy for MSA.

Great Northern Minerals Ltd (ASX: GNM) has announced a significant expansion of its Catalyst Ridge REE–Antimony Project in the Mountain Pass District, California (Figure 1). The move marks a step-change in the Company’s U.S. footprint, adding new ground in one of the world’s most strategic rare earth corridors.

Golden Dragon Mining Ltd (ASX: GDR) is set to list on the ASX on 14 October 2025, following a fully subscribed IPO raising A$5 million at $0.20 per share. With a post-money market cap of A$8.89M and an enterprise value of just ~A$3.7M, GDR offers investors an attractive entry point into a multi-project gold explorer positioned in one of Western Australia’s most productive gold provinces.

Every so often, we see a project cross an important threshold – the point where years of technical work and regulatory engagement transform from planning into physical activity on the ground. For Alligator Energy Limited (ASX: AGE), the Samphire Uranium Project near Whyalla, South Australia, has reached exactly that point (Figure 1). With final regulatory approvals secured, drilling underway, and construction about to follow, the project is now positioned to generate the crit

DY6 Metals Ltd (ASX: DY6) is advancing exploration at its gallium and rare earth projects in southern Malawi, a move that comes at a time when global demand for critical minerals is intensifying. The upcoming sampling programs at Tundulu and Machinga are designed to build on high-grade results already reported, positioning the Company to unlock further value in strategically important commodities (Figure 1).

Terra Critical Minerals Limited (ASX: T92) has reported further high-grade silver mineralisation from its 100% owned Castle Rag Project in New South Wales (Figure 1). The latest results build on previously reported intercepts and continue to highlight the project’s potential within the broader New England mineral field.

E79 Gold Mines Limited (ASX: E79) has delivered a promising exploration update from its Laverton South Gold Project (Figure 1), with significant gold intercepts reported from reconnaissance aircore drilling at the emerging T14 South gold prospect. These results reinforce the potential of this structurally complex target and open the door for near-term discovery catalysts as further assays are pending.

Proteomics International Laboratories (ASX: PIQ) has unveiled new results for its PromarkerEso blood test, a patented, first-in-class diagnostic that delivers a simple and scalable pathway for early detection. With clinical validation showing high accuracy in identifying early-stage EAC, PromarkerEso may well change the standard of care in managing this difficult disease. With patents already granted in Europe, China, and Australia—and other territories pending.

Actinogen Medical Limited (ASX: ACW) has announced a significant milestone in the development of Xanamem®, its lead therapy for Alzheimer’s disease (AD). Following a successful Type C meeting with the US Food and Drug Administration (FDA), the Company now has clear guidance on the remaining clinical, manufacturing, and regulatory requirements for a New Drug Application (NDA) submission in the US.